By Adem Lewis / in , , , , , /

NADAPTechnology’s two-part system reduces
the frequency of asthma attacks. The system is comprised of a pair of sensors and an attack
preventing nanoparticle-based treatment. Nanorods in the sensors are conjugated to nucleic acid
aptamers. When the aptamers bind to proteins, the nanorods release a low-frequency light,
which is detected by a spectrometer. An external sensor detects proteins in allergens, while
an internal sensor detects serum eosinophil cationic protein, also called sECP. sECP data
is then transmitted to a microchip in the external sensor. If allergen or sECP concentration
reaches a specific predetermined level, the patient is alerted to use the inhaler. Magnetic
nanoparticles from the inhaler travel into the bronchioles. The nanoparticles are either
conjugated to engineered high-affinity IgE receptors or Fcabs, which are engineered antibody
fragments. Immediately after allergens entering the body bind to IgE, nanoparticles with IgE
receptors will bind to the IgE-allergen complexes. At the same time, those nanoparticles with
Fcabs bind to immune cells. The polarity of the nanoparticles prevents IgE from binding
to the immune cells. NADAPTechnology will improve the lives of asthmatics by anticipating
and preventing asthma attacks.

Leave a Reply

Your email address will not be published. Required fields are marked *